Article
Philadelphia-The reality of light-adjustable IOLs for clinical use is on the horizon. Availability of technology such as this will eliminate the need to remove IOLs because of incorrect power, according to Nick Mamalis, MD.
Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300
(EyePod) From idea to impact: Navigating ophthalmic innovation
Study explores the true costs of treating pediatric cataracts
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
Raising cataract surgery procedure to an art and an experience